Skip to main content
SpringerLink
Log in
Book cover

Cancer Epigenetics pp 253–269Cite as

Epigenetics in Ovarian Cancer

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 863))

Abstract

Ovarian cancer is the most lethal gynecological cancer. Due to few early symptoms and a lack of early detection strategies, most patients are diagnosed with advanced-stage disease. Most of these patients, although initially responsive, eventually develop drug resistance. In this chapter, epigenetic changes in ovarian cancer are described. Various epigenetic changes including CpG island methylation and histone modification have been identified in ovarian cancer. These aberrations are associated with distinct disease subtypes and present in circulating serum of ovarian cancer patients. Several epigenetic changes have shown promise for their diagnostic, prognostic, and predictive capacity but still need further validation.

In contrast to DNA mutations and deletions, epigenetic modifications are potentially reversible by epigenetic therapies. Promising preclinical studies show epigenetic drugs to enhance gene re-expression and drug sensitivity in ovarian cancer cell lines and animal models.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J. (2009) Cancer statistics, 2009. CA Cancer J Clin 59, 225–249.

    Article  PubMed  Google Scholar 

  2. Barnholtz-Sloan, J.S., Schwartz, A.G., Qureshi, F., Jacques, S., Malone, J., Munkarah, A.R. (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189, 1120–1127.

    Article  PubMed  Google Scholar 

  3. Press, J.Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S.E., Blood, K.A., Smith, M., Spellman, P.T., Wang, Y., Miller, D.M., Horsman, D., Faham, M., Gilks, C.B., Gray, J., Huntsman, D.G. (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17.

    Article  PubMed  CAS  Google Scholar 

  4. Milde-Langosch, K., Ocon, E., Becker, G., Loning, T. (1998) p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79, 61–65.

    Article  PubMed  CAS  Google Scholar 

  5. Balch, C., Huang, T.H., Brown, R., Nephew, K.P. (2004) The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191, 1552–1572.

    Article  PubMed  CAS  Google Scholar 

  6. Ibanez de Caceres, I., Battagli, C., Esteller, M., Herman, J.G., Dulaimi, E., Edelson, M.I., Bergman, C., Ehya, H., Eisenberg, B.L., Cairns, P.(2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64, 6476–6481.

    Article  PubMed  Google Scholar 

  7. Sellar, G.C., Watt, K.P., Rabiasz, G.J., Stronach, E.A., Li, L., Miller, E.P., Massie, C.E., Miller, J., Contreras-Moreira, B., Scott, D., Brown, I., Williams, A.R., Bates, P.A., Smyth, J.F., Gabra, H. (2003) OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 34, 337–343.

    Article  PubMed  CAS  Google Scholar 

  8. Feng, W., Marquez, R.T., Lu, Z., Liu, J., Lu, K.H., Issa, J.P., Fishman, D.M., Yu, Y., Bast, R.C. Jr. (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489–1502.

    Article  PubMed  CAS  Google Scholar 

  9. Kwong, J., Lee, J.Y., Wong, K.K., Zhou, X., Wong, D.T., Lo, K.W., Welch, W.R., Berkowitz, R.S., Mok, S.C. (2006) Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8, 268–278.

    Article  PubMed  CAS  Google Scholar 

  10. Petrocca, F., Iliopoulos, D., Qin, H.R., Nicoloso, M.S., Yendamuri, S., Wojcik, S.E., Shimizu, M., Di Leva, G., Vecchione, A., Trapasso, F., Godwin, A.K., Negrini, M., Calin, G.A., Croce, C.M. (2006) Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 66, 10287–10291.

    Article  PubMed  CAS  Google Scholar 

  11. Chien, J., Staub, J., Avula, R., Zhang, H., Liu, W., Hartmann, L.C., Kaufmann, S.H., Smith, D.I., Shridhar, V. (2004) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24, 5089–5100.

    Article  CAS  Google Scholar 

  12. Cvetkovic, D., Pisarcik, D., Lee, C., Hamilton, T.C., Abdollahi, A. (2004) Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol Oncol 95, 449–455.

    Article  PubMed  CAS  Google Scholar 

  13. Pruitt, K., Ulku, A.S., Frantz, K., Rojas, R.J., Muniz-Medina, V.M., Rangnekar, V.M., Der, C.J., Shields, J.M. (2005) Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 280, 23363–23370.

    Article  PubMed  CAS  Google Scholar 

  14. Terasawa, K., Sagae, S., Toyota, M., Tsukada, K., Ogi, K., Satoh, A., Mita, H., Imai, K., Tokino, T., Kudo, R. (2004) Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10, 2000–2006.

    Article  PubMed  CAS  Google Scholar 

  15. Arnold, J.M., Cummings, M., Purdie, D., Chenevix-Trench, G. (2001) Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer 85, 1351–1358.

    Article  PubMed  CAS  Google Scholar 

  16. Yuecheng, Y., Hongmei, L., Xiaoyan, X. (2006) Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis; 23, 65–74.

    Article  PubMed  CAS  Google Scholar 

  17. Backen, A.C., Cole, C.L., Lau, S.C., Clamp, A.R., McVey, R., Gallagher, J.T., Jayson, G.C. (2007) Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer 96, 1544–1548.

    Article  PubMed  CAS  Google Scholar 

  18. Staub, J., Chien, J., Pan, Y., Qian, X., Narita, K., Aletti, G., Scheerer, M., Roberts, L.R., Molina, J., Shridhar, V. (2007) Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene 26, 4969–4978.

    Article  PubMed  CAS  Google Scholar 

  19. Potapova, A., Hoffman, A.M., Godwin, A.K., Al-Saleem, T., Cairns, P. (2008) Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 68, 998–1002.

    Article  PubMed  CAS  Google Scholar 

  20. Socha, M.J., Said, N., Dai, Y., Kwong, J., Ramalingam, P., Trieu, V., Desai, N., Mok, S.C., Motamed, K. (2009) Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11, 126–135.

    PubMed  CAS  Google Scholar 

  21. Kikuchi, R., Tsuda, H., Kozaki, K., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., Imoto, I. (2008) Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res 68, 5067–5075.

    Article  PubMed  CAS  Google Scholar 

  22. Kikuchi, R., Tsuda, H., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., Imoto, I. (2007) Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 67, 7095–7105.

    Article  PubMed  CAS  Google Scholar 

  23. Baldwin, R.L., Nemeth, E., Tran, H., Shvartsman, H., Cass, I., Narod, S., Karlan, B.Y. (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60, 5329–5333.

    PubMed  CAS  Google Scholar 

  24. Strathdee, G., Appleton, K., Illand, M., Millan, D.W., Sargent, J., Paul, J., Brown, R. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158, 1121–1127.

    Article  PubMed  CAS  Google Scholar 

  25. Catteau, A., Harris, W.H., Xu, C.F., Solomon, E. (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18, 1957–1965.

    Article  PubMed  CAS  Google Scholar 

  26. Geisler, J.P., Hatterman-Zogg, M.A., Rathe, J.A., Buller, R.E. (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94, 61–67.

    Article  PubMed  CAS  Google Scholar 

  27. Buller, R.E., Shahin, M.S., Geisler, J.P., Zogg, M., De Young, B.R., Davis, C.S. (2002) Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8, 1196–1202.

    PubMed  CAS  Google Scholar 

  28. Rathi, A., Virmani, A.K., Schorge, J.O., Elias, K.J., Maruyama, R., Minna, J.D., Mok, S.C., Girard, L., Fishman, D.A., Gazdar, A.F. (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8, 3324–3331.

    PubMed  CAS  Google Scholar 

  29. Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H.L., Strathdee, G., Brown, R. (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65, 8961–8967.

    Article  PubMed  CAS  Google Scholar 

  30. Bol, G.M., Suijkerbuijk, K.P., Bart, J., Vooijs, M., van der Wall, E., van Diest, P.J. (2010) Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57, 363–370.

    Article  PubMed  Google Scholar 

  31. Hilton, J.L., Geisler, J.P., Rathe, J.A., Hattermann-Zogg, M.A., DeYoung, B., Buller, R.E. (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94, 1396–1406.

    Article  PubMed  CAS  Google Scholar 

  32. Wilcox, C.B, Baysal, B.E., Gallion, H.H., Strange, M.A., DeLoia, J.A. (2005) High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159, 114–122.

    Article  PubMed  CAS  Google Scholar 

  33. Gras, E., Cortes, J., Diez, O., Alonso, C., Matias-Guiu, X., Baiget, M., Prat, J. (2001) Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92, 787–795.

    Article  PubMed  CAS  Google Scholar 

  34. Su, H.Y., Lai, H.C., Lin, Y.W., Chou, Y.C., Liu, C.Y., Yu, M.H. (2009) An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124, 387–393.

    Article  PubMed  CAS  Google Scholar 

  35. Fiegl, H., Windbichler, G., Mueller-Holzner, E., Goebel, G., Lechner, M., Jacobs, I.J., Widschwendter, M. (2008) HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer 123, 725–729.

    Article  PubMed  CAS  Google Scholar 

  36. Wei, S.H., Chen, C.M., Strathdee, G., Harnsomburana, J., Shyu, C.R., Rahmatpanah, F., Shi, H., Ng, S.W., Yan, P.S., Nephew, K.P., Brown, R., Huang, T.H. (2002) Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8, 2246–2252.

    PubMed  CAS  Google Scholar 

  37. Houshdaran, S., Hawley, S., Palmer, C., Campan, M., Olsen, M.N., Ventura, A.P., Knudsen, B.S., Drescher, C.W., Urban, N.D., Brown, P.O., Laird, P.W. (2010) DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One 5, e9359.

    Article  PubMed  CAS  Google Scholar 

  38. Akahira, J., Sugihashi, Y., Suzuki, T., Ito, K., Niikura, H., Moriya, T., Nitta, M., Okamura, H., Inoue, S., Sasano, H., Okamura, K., Yaegashi, N. (2004) Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10, 2687–2693.

    Article  PubMed  CAS  Google Scholar 

  39. Akahira, J., Sugihashi, Y., Ito, K., Niikura, H., Okamura, K., Yaegashi, N. (2004) Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci 95, 40–43.

    Article  PubMed  CAS  Google Scholar 

  40. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Yamada, H., Yamamoto, R., Sakuragi, N., Enokida, H., Verma, M., Dahiya, R.. (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104, 1924–1930.

    Article  PubMed  CAS  Google Scholar 

  41. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Verma, M., Ebina, Y., Nomura, E., Yamamoto, R., Sakuragi, N., Dahiya, R. (2004) Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316, 1156–1162.

    Article  PubMed  CAS  Google Scholar 

  42. Ehrlich, M. (2006) Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 310, 251–274.

    Article  PubMed  CAS  Google Scholar 

  43. Feinberg, A.P., Vogelstein, B. (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895):89–92.

    Article  PubMed  CAS  Google Scholar 

  44. Gama-Sosa, M.A., Midgett, R.M., Slagel, V.A., Githens, S., Kuo, K.C., Gehrke, C.W., Ehrlich, M. (1983) Tissue-specific differences in DNA methylation in various mammals. Biochim Biophys Acta 740, 212–219.

    Article  PubMed  CAS  Google Scholar 

  45. Strathdee, G., Vass, J.K., Oien, K.A., Siddiqui, N., Curto-Garcia, J., Brown, R. (2005) Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97, 898–903.

    Article  PubMed  CAS  Google Scholar 

  46. Czekierdowski, A., Czekierdowska, S., Wielgos, M., Smolen, A., Kaminski, P., Kotarski, J. (2006) The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 27, 381–386.

    PubMed  CAS  Google Scholar 

  47. Gupta, A., Godwin, A.K., Vanderveer, L., Lu, A., Liu, J. (2003) Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63, 664–673.

    PubMed  CAS  Google Scholar 

  48. Yao, X., Hu, J.F., Li, T., Yang, Y., Sun, Z., Ulaner, G.A., Vu, T.H., Hoffman, A.R. (2004) Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet 151, 1–13.

    Article  PubMed  CAS  Google Scholar 

  49. Woloszynska-Read, A., James, S.R., Link, P.A., Yu, J., Odunsi, K., Karpf, AR. (2007) DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 7, 21.

    PubMed  Google Scholar 

  50. Murphy, S.K., Huang, Z., Wen, Y., Spillman, M.A., Whitaker, R.S., Simel, L.R., Nichols, T.D., Marks, J.R., Berchuck, A. (2006) Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 4, 283–292.

    Article  PubMed  CAS  Google Scholar 

  51. Litkouhi, B., Kwong, J., Lo, C.M., Smedley, J.G., III, McClane, B.A., Aponte, M., Gao, Z., Sarno, J.L., Hinners, J., Welch, W.R., Berkowitz, R.S., Mok, S.C., Garner, E.I. (2007) Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9, 304–314.

    Article  PubMed  CAS  Google Scholar 

  52. Florl, A.R., Lower, R., Schmitz-Drager, B.J., Schulz, W.A. (1999) DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 80, 1312–1321.

    Article  PubMed  CAS  Google Scholar 

  53. Lorincz, M.C., Schubeler, D., Groudine, M. (2001) Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol Cell Biol 21, 7913–7922.

    Article  PubMed  CAS  Google Scholar 

  54. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., et al. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860–921.

    Article  PubMed  CAS  Google Scholar 

  55. Pattamadilok, J., Huapai, N., Rattanatanyong, P., Vasurattana, A., Triratanachat, S., Tresukosol, D., Mutirangura, A. (2008) LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18, 711–717.

    Article  PubMed  CAS  Google Scholar 

  56. Menendez, L., Benigno, B.B., McDonald, J.F. (2004) L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 3, 12.

    Article  PubMed  Google Scholar 

  57. Qu, G., Dubeau, L., Narayan, A., Yu, M.C., Ehrlich, M. (1999) Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 423, 91–101.

    Article  PubMed  CAS  Google Scholar 

  58. Widschwendter, M., Jiang, G., Woods, C., Muller, H.M., Fiegl, H., Goebel, G., Marth, C., Muller-Holzner, E., Zeimet, A.G., Laird, P.W., Ehrlich, M. (2004) DNA hypomethylation and ovarian cancer biology. Cancer Res 64, 4472–4480.

    Article  PubMed  CAS  Google Scholar 

  59. Zhang, K., Dent, S.Y. (2005) Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem 96, 1137–1148.

    Article  PubMed  CAS  Google Scholar 

  60. Santos-Rosa, H., Caldas, C. (2005) Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41, 2381–2402.

    Article  PubMed  CAS  Google Scholar 

  61. LaVoie, H.A. (2005) Epigenetic control of ovarian function: the emerging role of histone modifications. Mol Cell Endocrinol 243, 12–18.

    Article  PubMed  CAS  Google Scholar 

  62. Ozdag, H., Teschendorff, A.E., Ahmed, A.A., Hyland, S.J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M.J., Collins, V.P., Bowtell, D., Kouzarides, T., Brenton, J.D., Caldas, C. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7, 90.

    Google Scholar 

  63. Izutsu, N., Maesawa, C., Shibazaki, M., Oikawa, H., Shoji, T., Sugiyama, T., Masuda, T. (2008) Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 32, 1227–1235.

    PubMed  CAS  Google Scholar 

  64. Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., Wen, S.F., Wang, L., Kirschmeier, P., Bishop, W.R., Nielsen, L.L., Pickett, C.B., Liu, S. (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21, 2613–2622.

    Article  PubMed  CAS  Google Scholar 

  65. Fu, Y., Campbell, E.J., Shepherd, T.G., Nachtigal, M.W. (2003) Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 1, 569–576.

    PubMed  CAS  Google Scholar 

  66. Honda, H., Pazin, M.J., Ji, H., Wernyj, R.P., Morin, P.J. (2006) Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 281, 21433–21444.

    Article  PubMed  CAS  Google Scholar 

  67. Caslini, C., Capo-chichi, C.D., Roland, I.H., Nicolas, E., Yeung, A.T., Xu. X.X. (2006) Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25, 5446–5461.

    Article  PubMed  CAS  Google Scholar 

  68. Jin, K.L., Pak. J.H., Park, J.Y., Choi, W.H., Lee, J.Y., Kim, J.H., Nam, J.H. (2008) Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 19, 185–190.

    Article  PubMed  CAS  Google Scholar 

  69. Strait, K.A., Dabbas, B., Hammond, E.H., Warnick, C.T., Iistrup, S.J., Ford, C.D. (2002) Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1, 1181–1190.

    PubMed  CAS  Google Scholar 

  70. Lopez, J., Percharde, M., Coley, H.M., Webb, A., Crook, T. (2009) The context and potential of epigenetics in oncology. Br J Cancer 100, 571–577.

    Article  PubMed  CAS  Google Scholar 

  71. Schickel, R., Boyerinas, B., Park, S.M., Peter, M.E. (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27, 5959–5974.

    Article  PubMed  CAS  Google Scholar 

  72. Iorio, M.V., Visone, R., Di, L.G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.G., Alder, H., Calin, G.A., Menard, S., Croce, C.M. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67, 8699–8707.

    Article  PubMed  CAS  Google Scholar 

  73. Yang, H., Kong, W., He, L., Zhao, J.J., O’Donnell, J.D., Wang, J., Wenham, R.M., Coppola, D., Kruk, P.A., Nicosia, S.V., Cheng, J.Q. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68, 425–433.

    Article  PubMed  CAS  Google Scholar 

  74. Lee, C.H., Subramanian, S., Beck, A.H., Espinosa, I., Senz, J., Zhu, S.X., Huntsman, D., van de Rijn, M., Gilks, CB. (2009) MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4, e7314.

    Article  PubMed  CAS  Google Scholar 

  75. Corney, D.C., Hwang, C.I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A.K., Kamat, A.A., Sood, A.K., Ellenson, L.H., Hermeking, H., Nikitin, A.Y. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16, 1119–1128.

    Article  PubMed  CAS  Google Scholar 

  76. Teschendorff, A.E., Menon, U., Gentry-Maharaj, A., Ramus, S.J., Gayther, S.A., Apostolidou, S., Jones, A., Lechner, M., Beck, S., Jacobs, I.J., Widschwendter, M. (2009) An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 4, e8274.

    Article  PubMed  CAS  Google Scholar 

  77. Laird PW. (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3, 253–266.

    Article  PubMed  CAS  Google Scholar 

  78. Collins, Y., Dicioccio, R., Keitz, B., Lele, S., Odunsi, K. (2006) Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 16 Suppl 1, 195–199.

    Article  PubMed  Google Scholar 

  79. Chou, J.L., Su, H.Y., Chen, L.Y., Liao, Y.P., Hartman-Frey, C., Lai, Y.H., Yang, H.W., Deatherage, D.E., Kuo, C.T., Huang, Y.W., Yan, P.S., Hsiao, S.H., Tai, C.K., Lin, H.J., Davuluri, R.V., Chao, T.K., Nephew, K.P., Huang, T.H., Lai, H.C., Chan, M.W. (2010) Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90, 414–425.

    Article  PubMed  CAS  Google Scholar 

  80. Wiley, A., Katsaros, D., Chen, H., Rigault de la Longrais, I.A., Beeghly, A., Puopolo, M., Singal, R., Zhang, Y., Amoako, A., Zelterman, D., Yu, H. (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107, 299–308.

    Article  PubMed  CAS  Google Scholar 

  81. Chan, M.W., Wei, S.H., Wen, P., Wang, Z., Matei, D.E., Liu, J.C., Liyanarachchi, S., Brown, R., Nephew, K.P., Yan, P.S., Huang, T.H. (2005) Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 11, 7376–7383.

    Article  PubMed  CAS  Google Scholar 

  82. Wei, S.H., Balch, C., Paik, H.H., Kim, Y.S., Baldwin, R.L., Liyanarachchi, S., Li, L., Wang, Z., Wan, J.C., Davuluri, R.V., Karlan, B.Y., Gifford, G., Brown, R., Kim, S., Huang, T.H., Nephew, K.P. (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12, 2788–2794.

    Article  PubMed  CAS  Google Scholar 

  83. Muller, H.M., Millinger, S., Fiegl, H., Goebel, G., Ivarsson, L., Widschwendter, A., Muller-Holzner, E., Marth, C., Widschwendter, M. (2004) Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem 50, 2171–2173.

    Article  PubMed  CAS  Google Scholar 

  84. Wurz, K., Garcia, R.L., Goff, B.A., Mitchell, P.S., Lee, J.H., Tewari, M., Swisher, E.M. (2010) MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 49, 577–584.

    PubMed  CAS  Google Scholar 

  85. Leskela, S., Leandro-Garcia, L.J., Mendiola, M., Barriuso, J., Inglada-Perez, L., Munoz, I., Martinez-Delgado, B., Redondo, A., de Santiago, J., Robledo, M., Hardisson, D., Rodriguez Antona, C. (2010) miR-200 family controls {beta}-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer.

    Google Scholar 

  86. Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, N.V., Albarracin, C., Yu, D., Abbruzzese, J.L., Mills, G.B., Bast, R.C. Jr, Hortobagyi, G.N., Hung, MC. (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47, 701–706.

    Article  PubMed  CAS  Google Scholar 

  87. Weichert, W., Denkert, C., Noske, A., rb-Esfahani, S., Dietel, M., Kalloger, S.E., Huntsman, D.G., Kobel, M. (2008) Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10, 1021–1027.

    Google Scholar 

  88. Strathdee, G., MacKean, M.J., Illand, M., Brown, R. (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335–2341.

    Article  PubMed  CAS  Google Scholar 

  89. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B., Brown, R. (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60, 6039–6044.

    PubMed  CAS  Google Scholar 

  90. Brown, R., Hirst, G.L., Gallagher, W.M., McIlwrath, A.J., Margison, G.P., van der Zee, A.G., Anthoney, D.A. (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45–52.

    Article  PubMed  CAS  Google Scholar 

  91. Hofstetter, B., Niemierko, A., Forrer, C., Benhattar, J., Albertini, V., Pruschy, M., Bosman, F.T., Catapano, C.V., Ciernik, I.F. (2010) Impact of genomic methylation on radiation sensitivity of colorectal carcinoma. Int J Radiat Oncol Biol Phys 76, 1512–1519.

    Article  PubMed  CAS  Google Scholar 

  92. Fu, S., Hu, W., Iyer, R., Kavanagh, J.J., Coleman, R.L., Levenback, C.F., Sood, A.K., Wolf, J.K., Gershenson, D.M., Markman, M., Hennessy, B.T., Kurzrock, R., Bast, R.C. Jr. (2010) Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer.

    Google Scholar 

  93. Su, H.Y., Lai, H.C., Lin, Y.W., Liu, C.Y., Chen CK, Chou YC, Lin SP, Lin WC, Lee HY, Yu MH. (2010) Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127, 555–567.

    Article  PubMed  CAS  Google Scholar 

  94. Lee, P.S., Teaberry, V.S., Bland, A.E., Huang, Z., Whitaker, R.S., Baba, T., Fujii, S., Secord, A.A., Berchuck, A., Murphy, S.K. (2010) Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 126, 1378–1389.

    PubMed  CAS  Google Scholar 

  95. Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H., Mok, S.C., D’Andrea, A.D. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9, 568–574.

    Article  PubMed  CAS  Google Scholar 

  96. Boren, T., Xiong, Y., Hakam, A., Wenham, R., Apte, S., Chan, G., Kamath, S.G., Chen, D.T., Dressman, H., Lancaster, JM. (2009) MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113, 249–255.

    Article  PubMed  CAS  Google Scholar 

  97. Yang, N., Kaur, S., Volinia, S., Greshock, J., Lassus, H., Hasegawa, K., Liang, S., Leminen, A., Deng, S., Smith, L., Johnstone, C.N., Chen, X.M., Liu, C.G., Huang, Q., Katsaros, D., Calin, G.A., Weber, B.L., Butzow, R., Croce, C.M., Coukos, G., Zhang, L. (2008) MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68, 10307–10314.

    Article  PubMed  CAS  Google Scholar 

  98. Jones, P.A., Baylin, SB. (2007) The epigenomics of cancer. Cell 128, 683–692.

    Article  PubMed  CAS  Google Scholar 

  99. Esteller, M. (2008) Epigenetics in cancer. N Engl J Med 358, 1148–1159.

    Article  PubMed  CAS  Google Scholar 

  100. Li, Y., Hu, W., Shen, D.Y., Kavanagh, J.J., Fu, S. (2009) Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol 200, 177–179.

    PubMed  Google Scholar 

  101. Lenzi, R., Frost, P., Abbruzzese, J.L. (1994) Modulation of cisplatin resistance by 2′-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 14, 247–251.

    PubMed  Google Scholar 

  102. Balch, C., Yan, P., Craft, T., Young, S., Skalnik, D.G., Huang, T.H., Nephew, K.P. (2007) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4, 1505–1514.

    Article  CAS  Google Scholar 

  103. Takai, N., Narahara. H. (2007) Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14, 2548–2553.

    Article  PubMed  CAS  Google Scholar 

  104. Modesitt, S.C., Sill, M., Hoffman, J.S., Bender, D.P. (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109, 182–186.

    Article  PubMed  CAS  Google Scholar 

  105. Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J,, La Thangue, N.B., Brown, R. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2, 721–728.

    PubMed  CAS  Google Scholar 

  106. Arts, J., Angibaud, P., Marien, A., Floren, W., Janssens, B., King, P., van Dun, J., Janssen, L., Geerts, T., Tuman, R.W., Johnson, D.L., Andries, L., Jung, M., Janicot, M., van Emelen, K. (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97, 1344–1353.

    Article  PubMed  CAS  Google Scholar 

  107. Takai, N., Ueda, T., Nishida, M., Nasu, K., Narahara, H. (2006) A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med 17, 323–329.

    PubMed  CAS  Google Scholar 

  108. Shi, H., Wei, S.H., Leu, Y.W., Rahmatpanah, F., Liu, J.C., Yan, P.S., Nephew, K.P., Huang, T.H. (2003) Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 63, 2164–2171.

    PubMed  CAS  Google Scholar 

  109. Steele, N., Finn, P., Brown, R., Plumb, J.A. (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer, 100, 758-763.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Reproductive Medicine and Gynaecology, Gynaecological Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands

    L. M. S. Seeber

  2. Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands

    P. J. van Diest

Authors
  1. L. M. S. Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. J. van Diest
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. van Diest .

Editor information

Editors and Affiliations

  1. School of Medicine, Saba University, Saba, Dutch Antilles

    Ramona G. Dumitrescu

  2. National Institutes of Health (NIH), Div. Cancer Control &, National Cancer Institute, Executive Blvd. 6130Suite 5100, Bethesda, 20892-7324, Maryland, USA

    Mukesh Verma

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Seeber, L.M.S., van Diest, P.J. (2012). Epigenetics in Ovarian Cancer. In: Dumitrescu, R., Verma, M. (eds) Cancer Epigenetics. Methods in Molecular Biology, vol 863. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-612-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-612-8_15

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-611-1

  • Online ISBN: 978-1-61779-612-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation